

07 October 2021

#### **ASX ANNOUNCEMENT**

#### **Retirement of Chairman**

ImpediMed Limited (ASX.IPD) (**ImpediMed** or **Company**) advises that the Company's Chairman, Mr Scott Ward, has notified the Company that he will not seek re-election at the Company's annual general meeting (**AGM**) to be held Wednesday 10 November 2021 and will retire from the Company's Board at the conclusion of the AGM

Mr. Ward has been a Non-Executive Director of the Company since July 2013 and Chairman since November 2017. During this time, his contributions to the company have been significant. Under his guidance the Company has expanded its clinical offerings from a single indication of lymphoedema, to a broad range of new opportunities, including heart failure, renal failure, protein calorie malnutrition, and body composition. The Board thanks Scott for his contributions and leadership during his eight-year tenure as Director and Chairman and wish him all the very best.

"ImpediMed is now progressing to the next phase of its journey, focusing on the commercialization of lymphoedema, heart failure and renal failure opportunities. I believe that the company is well positioned to improve the quality of care for patients around the world and I would like to thank the board, management, employees and shareholders for their support over the past several years." said Scott Ward.

The Board has elected Mr Donald Williams to be the new Chairman, effective from the conclusion of the 2021 AGM. Mr Williams was appointed to the Board in 2017, chairs the Remuneration Committee and serves on the Audit and Risk Committee. He has more than 35 years in leadership roles as a Certified Public Accountant and Public Company Director. For over fifteen years at Ernst & Young and during his seven years at Grant Thornton, Don was focused on the Life Science Industry. His breadth of experience includes a diverse set of domestic and international companies, venture financings, public equity offerings, mergers and acquisitions and interaction with the US Securities and Exchange Commission and Public Accounting Oversight Board.

Approved for release by the Board of ImpediMed Limited.

# **Contact Details**

**Investor relations Contact:** 

Mike Bassett, ImpediMed T: +61 407 431 432

E: mbassett@impedimed.com

## About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

# About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: https://www.impedimed.com/products/sozo/.

## **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.